Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy

The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit o...

Descripción completa

Detalles Bibliográficos
Autores principales: Grassi, Paolo, Verzoni, Elena, Ratta, Raffaele, Mennitto, Alessia, de Braud, Filippo, Procopio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939993/
https://www.ncbi.nlm.nih.gov/pubmed/27462141
http://dx.doi.org/10.2147/DDDT.S104225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939993/
https://www.ncbi.nlm.nih.gov/pubmed/27462141
http://dx.doi.org/10.2147/DDDT.S104225

Ejemplares similares